Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00212810|
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : May 19, 2011
|Condition or disease||Intervention/treatment||Phase|
|Migraine Headache Classic Migraine Common Migraine||Drug: Topiramate||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||385 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study|
|Study Start Date :||September 2005|
|Actual Study Completion Date :||August 2007|
- The primary efficacy parameter will be whether or not a patient experiences 15 or more headache days (migraine and non-migraine) during the last 28 days of the study.
- Time to development of transformed migraine;occurrence of transformation as function of baseline headache days;change in the average rate of migraine days;percentage change in the average rate of migraine days;50%,75%, and 100% reduction in migraine days
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00212810
|Study Director:||Ortho McNeil Neurologics, Inc. Clinical Trial||Ortho-McNeil Neurologics, Inc.|